LLY
Eli Lilly and Company NYSE Listed Jun 1, 1972$975.31
After hrs
$950.19
+0.18%
Mkt Cap $918.5B
52w Low $623.78
68.9% of range
52w High $1133.95
50d MA $944.33
200d MA $914.58
P/E (TTM)
41.9x
EV/EBITDA
35.8x
P/B
32.6x
Debt/Equity
1.6x
ROE
77.8%
P/FCF
107.6x
RSI (14)
—
ATR (14)
—
Beta
0.50
50d MA
$944.33
200d MA
$914.58
Avg Volume
3.3M
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Lilly Corporate Center · Indianapolis, IN 46285 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | TNS | 6.97 | 8.55 | +22.7% | 934.60 | +1.5% | +3.1% | +3.6% | +5.8% | +5.6% | +4.3% | — |
| Feb 4, 2026 | TNS | 6.91 | 7.54 | +9.1% | 1107.12 | -3.8% | -7.8% | -4.4% | -5.6% | -7.5% | -8.3% | — |
| Oct 30, 2025 | TNS | 5.69 | 7.02 | +23.4% | 844.50 | -0.6% | +2.2% | +6.2% | +7.4% | +9.6% | +11.0% | — |
| Aug 7, 2025 | TNS | 5.60 | 6.31 | +12.7% | 640.86 | +2.2% | -2.4% | -0.9% | -0.2% | +3.1% | +6.8% | — |
| May 1, 2025 | TNS | 3.26 | 3.34 | +2.5% | 794.10 | +3.9% | +3.7% | +3.4% | -2.4% | -2.2% | -5.4% | — |
| Feb 6, 2025 | TNS | 5.03 | 5.32 | +5.8% | 870.37 | +0.7% | +0.9% | -0.2% | -0.6% | +0.3% | +0.2% | — |
| Oct 30, 2024 | TNS | 1.47 | 1.18 | -19.7% | 846.83 | -1.2% | -2.0% | -3.3% | -4.8% | -4.8% | -8.3% | — |
| Aug 8, 2024 | TNS | 2.60 | 3.92 | +50.8% | 845.31 | +1.7% | +5.5% | +4.6% | +7.4% | +10.2% | +10.2% | — |
| Apr 30, 2024 | TNS | 2.46 | 2.58 | +4.9% | 781.10 | -0.8% | -0.6% | -3.2% | -5.9% | -1.8% | -0.4% | — |
| Feb 6, 2024 | TNS | 2.22 | 2.49 | +12.2% | 705.03 | +0.8% | +2.9% | +4.3% | +5.0% | +4.6% | +5.4% | — |
| Nov 2, 2023 | TNS | -0.08 | 0.10 | +225.0% | 580.29 | -0.3% | -2.2% | +2.6% | +3.4% | +6.7% | +1.9% | — |
| Aug 8, 2023 | TNS | 1.98 | 2.11 | +6.6% | 521.60 | -0.2% | +0.9% | -0.0% | +1.3% | +3.1% | +4.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $934.60 | $948.95 | +1.5% | +3.1% | +3.6% | +5.8% | +5.6% | +4.3% |
| Apr 22 | Guggenheim | Maintains | Buy → Buy | — | $903.02 | $906.40 | +0.4% | +2.0% | +1.6% | -2.1% | -3.8% | -3.2% |
| Apr 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $955.19 | $963.69 | +0.9% | -1.6% | -2.7% | -3.4% | -5.3% | -5.4% |
| Apr 2 | BofA Securities | Maintains | Buy → Buy | — | $954.52 | $945.00 | -1.0% | -2.0% | -2.9% | -2.5% | -0.1% | +0.1% |
| Mar 30 | Guggenheim | Maintains | Buy → Buy | — | $878.24 | $888.48 | +1.2% | +1.0% | +4.7% | +8.7% | +6.5% | +5.6% |
| Mar 17 | HSBC | Downgrade | Hold → Reduce | — | $989.12 | $978.92 | -1.0% | -5.9% | -7.2% | -7.2% | -8.3% | -7.9% |
| Feb 10 | Freedom Broker | Upgrade | Hold → Buy | — | $1044.67 | $1050.66 | +0.6% | -1.9% | -2.8% | -0.6% | -0.4% | -0.8% |
| Feb 9 | Deutsche Bank | Maintains | Buy → Buy | — | $1058.18 | $1077.09 | +1.8% | -1.3% | -3.2% | -4.1% | -1.9% | -1.7% |
| Feb 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $1107.12 | $1065.50 | -3.8% | -7.8% | -4.4% | -5.6% | -7.5% | -8.3% |
| Feb 5 | JP Morgan | Maintains | Overweight → Overweight | — | $1107.12 | $1065.50 | -3.8% | -7.8% | -4.4% | -5.6% | -7.5% | -8.3% |
| Feb 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $1107.12 | $1065.50 | -3.8% | -7.8% | -4.4% | -5.6% | -7.5% | -8.3% |
| Feb 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1107.12 | $1065.50 | -3.8% | -7.8% | -4.4% | -5.6% | -7.5% | -8.3% |
| Feb 2 | Freedom Broker | Maintains | Hold → Hold | — | $1037.15 | $1037.57 | +0.0% | +0.7% | -3.2% | +6.7% | -1.6% | +2.0% |
| Jan 20 | Guggenheim | Maintains | Buy → Buy | — | $1038.40 | $1028.15 | -1.0% | +0.3% | +3.9% | +4.7% | +2.5% | +2.3% |
| Dec 15 | BofA Securities | Maintains | Buy → Buy | — | $1027.51 | $1032.55 | +0.5% | +3.4% | +2.6% | +1.4% | +2.9% | +4.3% |
| Dec 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $982.22 | $985.00 | +0.3% | +1.2% | +2.8% | +4.6% | +8.1% | +7.3% |
| Dec 4 | BMO Capital | Maintains | Outperform → Outperform | — | $1033.56 | $1032.63 | -0.1% | -1.8% | -2.2% | -3.5% | -5.0% | -3.9% |
| Dec 3 | Guggenheim | Maintains | Buy → Buy | — | $1046.12 | $1046.39 | +0.0% | -1.2% | -3.0% | -3.4% | -4.6% | -6.1% |
| Nov 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $1059.70 | $1056.77 | -0.3% | +1.0% | +4.7% | +4.2% | +1.5% | -0.2% |
| Nov 24 | Bernstein | Maintains | Outperform → Outperform | — | $1059.70 | $1056.77 | -0.3% | +1.0% | +4.7% | +4.2% | +1.5% | -0.2% |
| Nov 19 | Truist | Maintains | Buy → Buy | — | $1030.05 | $1029.64 | -0.0% | +1.9% | +1.3% | +2.9% | +3.9% | +7.8% |
| Nov 18 | JP Morgan | Maintains | Overweight → Overweight | — | $1021.70 | $1014.01 | -0.8% | +0.8% | +2.7% | +2.1% | +3.7% | +4.7% |
| Nov 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $1017.78 | $1010.09 | -0.8% | +0.5% | +0.7% | +0.4% | +1.2% | +3.1% |
| Nov 12 | Citigroup | Maintains | Buy → Buy | — | $988.62 | $993.12 | +0.5% | +2.9% | +3.5% | +3.7% | +3.3% | +4.2% |
| Nov 10 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $924.37 | $939.74 | +1.7% | +4.6% | +7.0% | +10.1% | +10.7% | +10.9% |
| Nov 10 | Freedom Capital Markets | Downgrade | Buy → Hold | — | $924.37 | $939.74 | +1.7% | +4.6% | +7.0% | +10.1% | +10.7% | +10.9% |
| Nov 10 | Freedom Broker | Downgrade | Buy → Hold | — | $924.37 | $939.74 | +1.7% | +4.6% | +7.0% | +10.1% | +10.7% | +10.9% |
| Nov 7 | UBS | Maintains | Buy → Buy | — | $937.44 | $931.17 | -0.7% | -1.4% | +3.1% | +5.5% | +8.6% | +9.1% |
| Nov 6 | BMO Capital | Maintains | Outperform → Outperform | — | $925.81 | $928.00 | +0.2% | +1.3% | -0.2% | +4.4% | +6.8% | +9.9% |
| Oct 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $844.50 | $839.16 | -0.6% | +2.2% | +6.2% | +7.4% | +9.6% | +11.0% |
| Oct 16 | Guggenheim | Maintains | Buy → Buy | — | $826.57 | $825.07 | -0.2% | -0.9% | -2.9% | -2.1% | -3.3% | -1.7% |
| Oct 8 | Guggenheim | Maintains | Buy → Buy | — | $843.63 | $850.00 | +0.8% | +0.2% | +1.4% | -1.2% | -2.9% | -3.7% |
| Oct 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $819.85 | $824.94 | +0.6% | +2.4% | +3.1% | +2.9% | +3.2% | +4.3% |
| Sep 17 | Berenberg | Downgrade | Buy → Hold | — | $764.71 | $761.49 | -0.4% | -0.6% | -0.2% | -1.7% | -1.3% | -2.3% |
| Sep 16 | JP Morgan | Maintains | Overweight → Overweight | — | $748.19 | $745.41 | -0.4% | +2.2% | +1.6% | +2.0% | +0.5% | +0.9% |
| Aug 27 | HSBC | Upgrade | Reduce → Hold | — | $736.03 | $736.96 | +0.1% | -0.3% | -0.6% | -0.5% | -0.1% | +0.2% |
| Aug 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $639.43 | $650.40 | +1.7% | +3.3% | +7.0% | +9.7% | +9.2% | +10.0% |
| Aug 13 | Guggenheim | Maintains | Buy → Buy | — | $639.43 | $650.40 | +1.7% | +3.3% | +7.0% | +9.7% | +9.2% | +10.0% |
| Aug 11 | Deutsche Bank | Maintains | Buy → Buy | — | $625.65 | $629.42 | +0.6% | +1.5% | +2.2% | +5.6% | +9.4% | +12.1% |
| Aug 8 | UBS | Maintains | Buy → Buy | — | $640.86 | $655.00 | +2.2% | -2.4% | -0.9% | -0.2% | +3.1% | +6.8% |
| Aug 8 | JP Morgan | Maintains | Overweight → Overweight | — | $640.86 | $655.00 | +2.2% | -2.4% | -0.9% | -0.2% | +3.1% | +6.8% |
| Jul 11 | Guggenheim | Maintains | Buy → Buy | — | $790.65 | $786.35 | -0.5% | +0.3% | +1.1% | -2.4% | -0.1% | -3.7% |
| Jul 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $786.92 | $789.67 | +0.3% | +0.5% | +0.8% | +1.6% | -1.9% | +0.4% |
| Jun 20 | Guggenheim | Maintains | Buy → Buy | — | $785.03 | $786.00 | +0.1% | -2.8% | -1.8% | -0.9% | +0.9% | +1.3% |
| May 2 | UBS | Maintains | Buy → Buy | — | $794.10 | $825.12 | +3.9% | +3.7% | +3.4% | -2.4% | -2.2% | -5.4% |
| Apr 28 | HSBC | Downgrade | Buy → Reduce | — | $884.54 | $870.44 | -1.6% | -0.8% | +0.1% | +1.6% | -10.2% | -6.9% |
| Apr 14 | Guggenheim | Maintains | Buy → Buy | — | $732.41 | $750.45 | +2.5% | +3.0% | +3.4% | +0.3% | +14.7% | +11.7% |
| Apr 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $726.24 | $704.40 | -3.0% | +3.8% | -0.7% | +0.8% | +3.9% | +4.3% |
| Apr 8 | Goldman Sachs | Upgrade | Neutral → Buy | — | $723.73 | $754.98 | +4.3% | +0.3% | +4.1% | -0.4% | +1.2% | +4.2% |
| Mar 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $911.06 | $904.80 | -0.7% | +2.0% | +0.2% | -4.6% | -8.9% | -9.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | LILLY ENDOWMENT INC | — | Sell | 2,208 | $996.18 | $2.2M | 91,881,150 | -2.72% | — |
| May 6, 2026 | LILLY ENDOWMENT INC | — | Sell | 13,620 | $995.23 | $13.6M | 91,883,358 | -2.72% | — |
8-K
Nektar Therapeutics -- 8-K Filing
May 8
8-K · 8.01
!! High
Kyverna Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Eli Lilly acquired Kyverna Therapeutics for an undisclosed amount, expanding its immunology portfolio with Kyverna's cell therapy candidates.
May 4
8-K
Eli Lilly and Company -- 8-K Filing
Eli Lilly's strong Q1 2026 results—revenue up 56% to $19.8B and EPS up 170% to $8.26—combined with raised full-year guidance demonstrate robust momentum despite Mounjaro/Zepbound price pressure, signaling sustained growth.
Apr 30
8-K · 5.02
!!! Very High
Vaxart, Inc. -- 8-K 5.02: Executive Change
Vaxart appoints James B. Breitmeyer as Chief Executive Officer, signaling leadership transition that investors should monitor for strategic direction and operational changes.
Apr 23
8-K · 1.02
!! High
Rigel Pharmaceuticals Inc. (New) -- 8-K 1.02: Material Agreement Terminated
Rigel Pharmaceuticals terminated its CNS disease program effective June 15, 2026, eliminating a potential revenue stream and narrowing its pipeline focus to other therapeutic areas.
Apr 21
8-K · 7.01
! Medium
Neurogene, Inc. -- 8-K 7.01: Regulation FD Disclosure
Neurogene disclosed material information via press release but the 8-K summary doesn't specify the content, so investors should review Exhibit 99.1 directly to assess relevance to NGNE stock.
Apr 20
8-K
Unknown — 8-K Filing
LLY's acquisition of a target company includes contingent value rights tied to future milestones, meaning shareholders benefit only if specific operational or financial goals are met, adding execution risk to the deal.
Mar 31
8-K
Unknown — 8-K Filing
Directors gain broad indemnification coverage for legal expenses and settlements, which may reduce accountability for questionable decisions and increase shareholder litigation risk and governance concerns.
Mar 26
8-K · 7.01
! Medium
Zura Bio Limited Class A -- 8-K 7.01: Regulation FD Disclosure
Zura Bio disclosed material information via press release on February 23, 2026, subject to Regulation FD requirements without admitting materiality determinations for investor consideration.
Feb 23
8-K
Eli Lilly & Co. -- 8-K Filing
Eli Lilly exceeded expectations with Q4 2025 revenue surging 43% to $19.3 billion, driven by blockbuster diabetes drugs Mounjaro and Zepbound, while EPS jumped 51% to $7.39 reported.
Feb 4
Data updated apr 25, 2026 7:22pm
· Source: massive.com